Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 10, 2013, Pages 979-988

  De Ledinghen V ^a,b   Vergniol, J ^a   Barthe, C ^a   Foucher, J ^a,c   Chermak, F ^a   Le Bail, B ^b,d   Merrouche, W ^a   Bernard, P H ^c  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d HÔPITAL PELLEGRIN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTITEST SCORE; ADULT; APRI; ARTICLE; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIGESTIVE TRACT PARAMETERS; DISEASE SEVERITY; FACTORIAL ANALYSIS; FEMALE; FIB 4; FIBROTEST SCORE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER STIFFNESS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SURVIVAL RATE; SURVIVAL TIME; VIRUS CARRIER;

ADULT; BIOLOGICAL MARKERS; BIOPSY; DNA, VIRAL; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS B ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84876479904     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12307     Document Type: Article

References (44)

1. Bedossa P, Dargere D, Paradis V,. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
2. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD,. Liver biopsy. Hepatology 2009; 49: 1017-44.
3. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R,. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
4. Kamath PS, Kim WR,. The model for end-stage liver disease (MELD). Hepatology 2007; 45: 797-805.
5. Poynard T,. First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy. J Hepatol 2011; 54: 586-7.
6. Poynard T, Ngo Y, Munteanu M, Thabut D, Ratziu V,. Noninvasive markers of hepatic fibrosis in chronic hepatitis B. Curr Hepat Rep 2011; 10: 87-97.
7. Kim BK, Kim SU, Kim HS, et al,. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS ONE 2012; 7: e35825.
8. Ngo Y, Munteanu M, Messous D, et al,. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52: 1887-96.
9. Vergniol J, Foucher J, Terrebonne E, et al,. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-79.
10. Morra R, Lebray P, Ingiliz P, et al,. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. Hepatology 2008; 47: 353-4; author reply 354-6.
11. Naveau S, Gaude G, Asnacios A, et al,. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105.
12. Wai CT, Greenson JK, Fontana RJ, et al,. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
13. Sterling RK, Lissen E, Clumeck N, et al,. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
14. Nunes D, Fleming C, Offner G, et al,. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-53.
15. de Ledinghen V, Vergniol J,. Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices 2010; 7: 811-23.
16. Wong VW, Vergniol J, Wong GL, et al,. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51: 454-62.
17. Fraquelli M, Rigamonti C, Casazza G, et al,. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-73.
18. de Ledinghen V, Douvin C, Kettaneh A, et al,. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175-9.
19. Castera L, Vergniol J, Foucher J, et al,. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.
20. Friedrich-Rust M, Ong MF, Martens S, et al,. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74.
21. Marcellin P, Ziol M, Bedossa P, et al,. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int 2009; 29: 242-7.
22. Chan HL, Wong GL, Choi PC, et al,. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat 2009; 16: 36-44.
23. Vigano M, Paggi S, Lampertico P, et al,. Dual cut-off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation. Aliment Pharmacol Ther 2011; 34: 353-62.
24. Foucher J, Chanteloup E, Vergniol J, et al,. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-8.
25. Fung J, Lai CL, Seto WK, Wong DK, Yuen MF,. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. J Viral Hepat 2011; 18: 738-44.
26. Jung KS, Kim SU, Ahn SH, et al,. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53: 885-94.
27. Kim SU, Lee JH, Kim do Y, et al,. Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS ONE 2012; 7: e36676.
28. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T,. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-75.
29. Forns X, Ampurdanes S, Llovet JM, et al,. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92.
30. Castera L, Foucher J, Bernard PH, et al,. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-35.
31. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20: 15-20.
32. Zhou X, Obuchowski N, McClish D,. Statistical Methods in Diagnostic Medicine. 1st edn. New York: John Wiley & Sons, 2002.
33. DeLong ER, DeLong DM, Clarke-Pearson DL,. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44: 837-45.
34. Lambert J, Halfon P, Penaranda G, Bedossa P, Cacoub P, Carrat F,. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008; 54: 1372-78.
35. Obuchowski NA,. An ROC-type measure of diagnostic accuracy when the gold standard is continuous-scale. Stat Med 2006; 25: 481-93.
36. Hillis SL, Obuchowski NA, Schartz KM, Berbaum KS,. A comparison of the Dorfman-Berbaum-Metz and Obuchowski-Rockette methods for receiver operating characteristic (ROC) data. Stat Med 2005; 24: 1579-1607.
37. Hintze J,. NCSS 2003 User Guide. Kaysville, UT: Number Cruncher Statistical Systems, 2003.
38. Kremer JM, Lee RG, Tolman KG,. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy. A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989; 32: 121-7.
39. Taylor BC, Yuan JM, Shamliyan TA, Shaukat A, Kane RL, Wilt TJ,. Clinical outcomes in adults with chronic hepatitis B in association with patient and viral characteristics: A systematic review of evidence. Hepatology 2009; 49: S85-95.
40. Poynard T, Ngo Y, Perazzo H, et al,. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 2011; 7: 445-54.
41. Ngo Y, Benhamou Y, Thibault V, et al,. An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (FibroTest-ActiTest) and viral load. PLoS ONE 2008; 3: e2573.
42. Wong GL, Wong VW, Choi PC, Chan AW, Chan HL,. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010; 31: 1095-103.
43. Vergniol J, Foucher J, Castera L, et al,. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009; 16: 132-40.
44. Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y,. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat 2009; 16: 203-13.